Statistics from Altmetric.com
Congenital cytomegalovirus (cCMV) affects 0.3% of all babies born in the UK and accounts for 20% of all childhood sensorineural hearing loss.1 Samples need to be taken in the first 3 weeks of life to confirm congenital infection. Treatment using oral valganciclovir has been shown in a recent randomised controlled trial to prevent hearing deterioration and improve neurocognitive outcomes when started in the first month of life.2 In the absence of a screening programme, the great majority of affected infants are detected in early childhood when no randomised studies have yet shown treatment to be effective. A multicentre cohort study showed that testing for cCMV in …
Contributors SK designed the study, developed the first draft of the questionnaire, analysed results and wrote the first draft of the manuscript. SW helped with every revision of the questionnaire, disseminated the survey and contributed to writing the manuscript. LS helped draft the questionnaire, analysed results and contributed to writing the manuscript. SL helped draft the questionnaire and contributed to writing the manuscript. PDG helped draft the questionnaire and contributed to writing the manuscript. MS helped design the study, drafted the questionnaire and wrote the first draft of the manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.